New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
05:11 EDTTKPYY, TEVATeva, Takeda Pharmaceutical agree to commercialize rasagilinein Japan
Teva Pharmaceutical (TEVA) and Takeda Pharmaceutical (TKPYY) have signed an agreement allowing Takeda to commercialize Tevaís innovative treatment for Parkinsonís disease, rasagiline in Japan. Developed by Teva, rasagiline tablets are approved in over 40 countries for the treatment of Parkinsonís disease. Teva developed this product and received its first approval in 2005 in Israel and Europe, and is currently working towards the acquisition of marketing approval of this product in Japan. Under the terms of the agreement, Takeda will develop rasagiline tablets for the Japanese market and submit a New Drug Application for registration of the product in Japan. The financial details of the agreement are confidential.
News For TEVA;TKPYY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
10:28 EDTTEVASenate Health, Education, Labor & Pensions Committee to hold a hearing
The Subcommittee on Primary Health and Aging holds a hearing entitled, "Why Are Some Generic Drugs Skyrocketing In Price?" with President & CEO Vigodman of Teva Pharmaceutical and President & CEO Bedrosian of Lannett Company on November 20 at 1 pm. Webcast Link
07:42 EDTTEVAIntellipharmaceutics notes launch of 5mg strength Focalin XR by Teva
Subscribe for More Information
November 19, 2014
07:52 EDTTKPYYInforma Business Information to hold a conference
Subscribe for More Information
November 18, 2014
11:22 EDTTEVATeva patent victory over Warner Chilcott, Roche affirmed
The U.S. Court of Appeals for the Federal Circuit ruled that a district court was correct to grant summary judgment to Teva (TEVA) in a patent dispute with Warner Chilcott and Roche (RHHBY) over patents related to osteoporosis drug risedronate.
10:08 EDTTEVATeva calls active on renewed takeover chatter
Teva November 57 and 58 calls are active on total call volume of 21K contracts (2K puts) following renewed takeover chatter. November call option implied volatility is at 18, December is at 19; compared to its 26-week average of 24 according to Track Data. Active call volume suggests traders taking positions for upside price movement.
09:47 EDTTEVARumor: Teva moves up on renewed takeover chatter
Subscribe for More Information
08:00 EDTTEVATeva launches liquid formulation of TREANDA injection in the U.S.
Subscribe for More Information
November 12, 2014
17:33 EDTTKPYYSucampo files patent infringement suit against Dr. Reddy's Labs
Subscribe for More Information
November 11, 2014
08:01 EDTTKPYYGE Healthcare, Takeda enter into alliance agreement for R&D in hepatic fibrosis
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use